• 基本信息
    导师姓名： 赵维莅 学科代码： 100201
    性别： 女 学科名称： 内科学
    培养单位： 附属瑞金医院 三级学科 血液病
    导师类型： 博士生导师 专业领域名称： 内科学 专业学位
    联系方式： 专业领域代码： 105101
    邮编： 200020 邮箱地址： Zhao.weili@yahoo.com
  • 研究方向 (点击浏览详细信息)
  • 社会任职
     
    Biomarker Res编委
    中国病理生理学会理事
    美国血液学会外籍委员
    中国病理生理学会理事
    临床血液学杂志编委
    Pathobiology编委
    中国病理生理学会中国实验血液学分会常委
    白血病淋巴瘤杂志编委
    中华医学会血液学分会副主任委员
    中华医学会血液学分会淋巴细胞疾病学组副组长
    药学进展 副主编
    中华血液学杂志编委
    中国临床肿瘤协会抗淋巴瘤联盟副主席
    中国病理生理学会中国实验血液学分会秘书长
    上海市医学会血液学专科分会候任主任委员
  • 科研项目
    项目编号项目名称课题来源起止年月批准经费承担职责
    2022YFC2502600T细胞淋巴瘤/白血病进展演变机制及个体化精准诊疗体系国家科技部重点研发计划 2022-11~2025-12 1490万元  课题负责人
    82130004谷氨酰胺代谢异常导致NK/T细胞淋巴瘤免疫微环境失衡的分子机制和靶向干预国家自然科学基金重点项目 2022-01~2026-12 290万元  课题负责人
    SHDC2020CR1032BR-DA-EDOCH对比R-CEOP90方案联合ASCT治疗年轻高危弥漫大B细胞淋巴瘤安全性及有效性的多中心、观察性临床研究上海申康重大临床研究项目 2020-10~2022-09 715万元  课题负责人
    81830007组蛋白修饰异常导致B淋巴细胞恶变的分子机制和靶向干预国家自然科学基金/重点项目 2019-01~2023-12 294万元  课题负责人
    YFC0902801白血病分子分型精细图谱构建及新型分子标志发现 ，国家重点研发计划项目国家重点研发计划 2016-07~2018-10 100万元  课题负责人
    81520108003微小RNA/Ras信号通路在肿瘤血管介导淋巴瘤细胞免疫国家自然科学基金 2016-01~2020-12 235万元  课题负责人
    81325003淋巴细胞疾病国家杰出青年科学基金 2014-01~2016-12 200万元  课题负责人
    13XD1402700AMPK/mTOR通路调控恶性淋巴细胞自噬的机制研究和靶向干预上海市科委优秀学术带头人 2013-05~2015-12 40万元  课题负责人
    11JC1407300运用代谢组学方法研究淋巴瘤疾病进展的分子标志上海市科委重点项目 2012-01~2014-12 30万元  课题负责人
    81172254T细胞淋巴瘤NF-kappaB信号通路组蛋白乙酰化修饰的研究国家自然科学基金面上项目 2012-01~2015-12 60万元  课题负责人
    09SG21毛萼乙素抗淋巴瘤作用及其机制研究上海市教委曙光计划 2010-01~2012-12 15万元  课题负责人
    09QH1401700血管内皮细胞促T细胞淋巴瘤生长的调控机制及干预治疗的研究上海市科委青年科技启明星跟踪资助项目 2009-07~2011-06 20万元  课题负责人
    08410708800凋亡相关基因在恶性淋巴瘤中的表达调控机制及其生物学作用上海市科委国际合作项目 2008-09~2010-09 30万元  课题负责人
    30700335PRDM1基因beta异构型在弥漫大B细胞性淋巴瘤中的表达及其生物学作用国家自然基金委青年科学基金项目 2008-01~2010-12 17万元  课题负责人
    NCET-07-0556弥漫大B细胞淋巴瘤分子分型国家教育部“新世纪优秀人才支持计划” 2007-10~2010-12 50万元  课题负责人
    2006aa02a301癌症的基因组重排研究国家科技部“863”计划重大项目 2007-01~2009-12 756万元  课题负责人
    05QMX1429T细胞淋巴瘤血管内皮生长因子A表达和抗血管治疗的研究上海市科委启明星 2005-09~2008-09 10万元  课题负责人
  • 学术论文
    作者论文标题期刊名出版年卷期页码
    Shen R, Fu D, Dong L, Zhang MC, Shi Q, Shi ZY, Cheng S, Wang L, Xu PP, Zhao WL   Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma  Signal Transduct Target Ther  2024  8(1):145.  
    Zhong H, Cheng S, Zhang X, Xu B, Chen J, Jiang X, Xiong J, Hu Y, Cui G, Wei J, Qian W, Huang X, Hou M, Yan F, Wang X, Song Y, Hu J, Liu Y, Ma X, Li F, Wu C, Chen J, Yu L, Bai O, Xu J, Zhu Z, Liu L, Zhou X, Huang L, Tong Y, Niu T, Wu D, Zhang H, Wang C, Ouyang B, Yi H, Song Q, Cai G, Li B, Liu J, Li Z, Xiao R, Wang L, Jiang Y, Liu Y, Zheng X, Xu P, Huang H, Wang L, Chen S,  Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study  Innovation (Camb).  2023  4(3):100426 
    Qin W, Wang N, Shi Q, Sun R, Zheng Z, Fu D, Dong L, Li C, Zhang Y, Xu P, Cheng S, Qian Y, Feng Y, Wang L,  Genomic and transcriptomic characterization reveals B-cell hyperactivation and immune evasion in hepatitis B virus-associated diffuse large B-cell lymphoma  Clin Transl Med  2023  13(6):e1293.  
    Shi Q, He Y, Yi HM, Mu RJ, Jiang XF, Fu D, Dong L, Qin W, Xu PP, Cheng S, Song Q, Chen SJ, Wang L,  Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.   Cancer Commun (Lond).   2023  43(8):896-908. 
    XU PP,Huo YJ,  All roads lead to targeted diffuse large B-cell lymphoma approaches  Cancer Cell  2022  40(2):131-133 
    Lu H, Xu X, Fu D, Gu Y, Fan R, Yi H, He X, Wang C, Ouyang B, Zhao P, Wang L, Xu P, Cheng S, Wang Z, Zou D, Han L,  Butyrate-Producing Eubacterium rectale Suppress Lymphomagenesis by alleviating the TNF-induced TLR4/MYD88/NF-κB Axis  Cell Host & Microbe  2022  30(8):1139-1150 
    Wang N, Qin W, Zheng Z, Zhao M, Xiong J, Fang H, Sun R, Wang Y, Li C, Dong L, Sun X, Wang L, Xu P, Cheng S, Xu H, Zhang F,  Hepatitis B virus-associated follicular lymphoma presents T-cell inflamed phenotype and response to lenalidomide.   Cancer Commun (Lond)  2022  42(2):170-174 
    Huo YJ, Xu PP, Fu D, Yi HM, Huang YH, Wang L, Wang N, Ji MM, Liu QX, Shi Q, Wang S, Cheng S, Feng Y, Zhao WL.   Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication  Blood Cancer J  2022  12(3):48 
    Sun R, Zhang PP, Weng XQ, Gao XD, Huang CX, Li W, Hu XX, Xu PP, Cheng L, Jiang L, Fu D, Qu B, Zhao Y, Feng Y, Dou HJ, Zheng Z,  Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells.  Signal Transduct Target Ther  2022  7(1):80 
    Huo YJ, Xu PP, Fu D, Yi HM, Huang YH, Wang L, Wang N, Ji MM, Liu QX, Shi Q, Wang S, Cheng S, Feng Y, Zhao WL.   Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication  Blood Cancer J  2022  12(3):48 
    Xu PP, Shi ZY, Qian Y, Cheng S, Zhu Y, Jiang L, Li JF, Fang H, Huang HY, Yi HM, Ouyang BS, Wang L, Zhao WL.   Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study.  Lancet Healthy Longev.   2022  3(7):e481-e490 
    Fang Y, Zhang MC, Xu PP, Zhang SJ, Wang L, Cheng S, Fu D, Chang CK, Sun XJ, Zhao Y, Tang YJ, Tian X, Yi HM, Liu F,  Integrative genome-wide chromatin accessibility and transcriptome profiling of diffuse large B-cell lymphoma.  Clin Transl Med  2022  12(7):e975 
    Huo YJ, Xu PP, Wang L, Zhong HJ, Fu D, Shi Q, Cheng S, Wang S, Zhang MC,  Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma.  Biomark Res  2022  10(1):51 
    Huang YH, Cai K, Xu PP, Wang L, Huang CX, Fang Y, Cheng S, Sun XJ, Liu F, Huang JY, Ji MM,  CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis  Signal Transduct Target Ther  2021  6(1):10 
    Wang S, Wang L, Hu J, Qian W, Zhang X, Hu Y, Zhu Q, Chen B, Wu D, Chang CH, Xu P, Zheng X, Wei J, Liu Y, Cui G, Tang Y, Ma Y, Huang H, Yi H,  Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China  Cancer Commun  2021  41(3):229-239 
    Xiong J, Cui BW, Wang N, Dai YT, Zhang H, Wang CF, Zhong HJ, Cheng S, Ou-Yang BS, Hu Y, Zhang X, Xu B, Qian WB, Tao R, Yan F, Hu JD, Hou M, Ma XJ, Wang X, Liu YH, Zhu ZM, Huang XB, Liu L, Wu CY, Huang L, Shen YF, Huang RB, Xu JY, Wang C, Wu DP, Yu L, Li JF, Xu PP, Wang L, Huang JY, Chen SJ,  Genomic and transcriptomic characterization of natural-killer T-cell lymphoma  Cancer Cell  2020  37（3）：403-419 
    Cai MC, Cheng S, Wang X, Hu JD, Song YP, Huang YH, Yan ZX , Jiang YJ, Fang XS, Zheng XY, Dong LH, Ji MM, Wang L ,Xu PP,  CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial  Genome Medicine  2020  12 (1) : 41 
    Shen R, Xu PP, Wang N, Yi HM, Dong L, Fu D, Huang JY, Janin A,Cheng S,Wang L,  Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma  Clin Transl Med  2020  10(7):221 
    Wang L, Qin W, Huo YJ, Li X, Shi Q,Rasko John E J ,Janin A,  Advances in targeted therapy for malignant lymphoma  Signal Transduct Target Ther  2020  5(1):15 
    Cao YW, Liu Z, Wu W, Qian Y, Shi Q, Shen R, Ouyang B, Xu P, Cheng S, Ye J, Lu Y, Wang C, Yang C, Wang L,  Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma  Front Med  2019  13(1):94-103 
    Xu PP, Fu D, Li JY, Hu JD, Wang X, Zhou JF, Yu H, Zhao X, Huang YH, Jiang L, Liu F, Su LP, Chen ZW, Zeng QS, Chen JP, Fang MY, Ma J, Liu T, Song YP, Yu K, Li Y, Qiu LG, Chen XQ, Gu J, Yan JS, Hou M, Huang HY, Wang L, Cheng S, Shen Y, Xiong H, Chen SJ,  Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial  Lancet Haematol  2019  6(6):328-337 
    Yan ZX, Li L, Wang W, OuYang BS, Cheng S, Wang L, Wu W, Xu PP, Muftuoglu M, Hao M, Yang S, Zhang MC, Zheng Z, Li J,  Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma  Clin Cancer Res  2019  25(23):6995-7003 
    Zheng Z, Sun R, Zhao HJ, Fu D, Zhong HJ, Weng XQ, Qu B, Zhao Y, Wang L,  MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells  Mol Cancer  2019  18(1):54 
    Xiong J,  Targetable Metabolic Vulnerability in Diffuse Large B-Cell Lymphoma  EBioMedicine  2018  28;5–6 
    Ji MM, Huang YH, Huang JY, Wang ZF, Fu D, Liu H, Liu F, Leboeuf C, Wang L, Ye J, Lu YM, Janin A, Cheng S,  Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified  Haematologica  2018  103(4):679-687 
    Fang Y,Wang H,Dou HJ,Fan X,Fei XC, Cheng S,Janin A,Wang L,  Doxorubicin-loaded dextran-based nano-carriers for highly efficient inhibition of lymphoma cell growth and synchronous reduction of cardiac toxicity  Int J Nanomedicine  2018  13;5673–5683 
    Xu PP,Sun C, Cao X, Zhao X, Dai HJ, Lu S, Guo JJ, Fu SJ, Liu YX , Li SC, Chen M, McCord R, Venstromd J, Glusman ES, Punnoose E, Kiermaier A, Cheng G,  Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies  EBioMedicine  2018  33;94-104 
    Zheng Z, Xu PP, Wang L, Zhao HJ, Weng XQ, Zhong HJ, Qu B, Xiong J, Zhao Y, Wang XF, Janin A,  MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells  Journal of Experimental & Clinical Cancer Research  2017  36:82 
    Xiong J, Wang L, Fei XC, Jiang XF, Zheng Z, Zhao Y, Wang CF, Li B, Chen SJ, Janin A, Gale RP,  MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma  Blood Cancer Journal  2017  7; e582 
    Xu PP, Zhong HJ, Huang YH, Gao XD, Zhao X, Shen Y, Cheng S, Huang JY, Chen SJ, Wang L,  B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma：A Restropective Cohort Study  EBioMedicine  2017  16;106–114 
    Ji MM, Wang L, Zhan Q, Xue W, Zhao Y, Zhao X, Xu PP, Shen Y, Liu H, Janin A, Cheng S,  Induction of autophagy by valproic acid enhanced lymphoma cell chemo-sensitivity through an HDAC-independent IP3-mediated PRKAA/AMPK activation  Autophagy  2015  11:10,1-12 
    Xiong J, Bian J, Wang L, Zhou JY, Wang Y, Zhao Y, Wu LL, Hu JJ, Li B, Chen SJ, Yan C,  Dysregulated choline metabolism in T-cell lymphoma: role of choline kinase-α and therapeutic targeting  Blood Cancer J.  2015  13;5:287. doi: 10.1038/ 
    Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, Pan CM, Hu Y, Cai CP, Dong Y, Huang JY, Wang L, Shen Y, Meng GY, Zhou JF, Hu JD, Wang JF, Liu YH, Yang LH, Zhang F, Wang JM, Wang Z, Peng ZG, Chen FY, Sun ZM, Ding H, Shi JM, Hou J, Yan JS, Shi JY, Xu L, Li Y, Lu J, Zheng Z, Xue W,, Chen Z, Chen SJ  Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma  Nature Genetics  2015  47(9):1061-6  
    Zhang L, Chen QS, Xu PP, Qian Y, Wang AH, Xiao D, Zhao Y, Sheng Y, Wen XQ,  Catechins induced acute promyelocytic leukemia cell apoptosis and triggered PML-RARα oncoprotein degradation  J Hematol Oncol.   2014  7(1):75 
    Xu PP, Yu D, Wang L, Shen Y, Shen ZX,  Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients  Ann Hematol.  2014  94(2):239-47 
    Yan ZX, Wu LL, Xue K, Zhang QL, Guo Y, Romero M, Leboeuf C, Janin A, Chen SJ, Wang L,  MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma  LEUKEMIA  2014  28(4):880-887 
    Zheng Z, Cheng S, Wu W, Wang L, Zhao Y, Shen Y,  c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors  J Hematol Oncol.  2014  7(1):88 
    Yang F, Xiong J, Jia XE, Gu ZH, Shi JY, Zhao Y, Li JM, Chen SJ,  GSTT1 deletion is related to polycyclic aromatic hydrocarbons-induced DNA damage and lymphoma progression  PLoS One  2014  9(2):e89302. doi: 10.1371/journal.pone.0089302 
    Dong LH, Cheng S, Zheng Z, Wang L, Shen Y, Shen ZX, Chen SJ,  Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma  J Hematol Oncol.  2013  6:53. doi: 10.1186/1756-8722-6-53 
    Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, Chen SJ, Chen Y,  Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibitionof mTOR pathway and induction of autophagy  Cell Death Dis  2012  1;3:e275 
    Xu PP, Wang Y, Shen Y, Wang L, Shen ZX,  Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells. Prognostic factors of Chinese patients with T/NK-cell lymphoma: a single institution study of 170 patients  Med Oncol  2012  29(3):2176-82 
    Wang L, Shi WY, Yang F, Tang W, Gapihan G, Varna M, Shen ZX, Chen SJ, Leboeuf C, Janin A,  Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells  Haematologica.  2011  96(6):927-31 
    Shi WY, Wang L, Xiao D, Yao Y, Yang F, Jiang XX, Leboeuf C, Janin A, Chen SJ,  Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma  Ann Hematol  2011  90(1): 53-56 
    Tang W, Wang L,, Chen YB, Shen ZX, Hu J  Inttravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia  Biol Blood Marrow Transplant  2011  17(10):1555-61 
    Zhang YW, Jiang XX, Chen QS, Shi WY, Wang L, Sun HD, Shen ZX, Chen Z, Chen SJ,  Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways  Exp Hematol.  2010  38(3):191-201 
      Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways  Leukemia  2010  24(1):13-21 
    Xia ZG, Xu ZZ,, Zhao SQ, Ding F, Chen Y, Chen QS, Zheng Y, Zhu Q, Hu JP, Shen ZX, Li JM  The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment  Ann Hematol.  2010  89(2):171-7 
    Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ,  The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis  Leukemia  2009  23(8):1507-1514 
    Shen Y, Yao Y, Li JM, Mi JQ, Chen QS, Chen Y,, You JH, Zhao HJ, Wang Y, Wang L, Cheng S, Shen ZX  Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population  Ann Hematol.  2009  88(9):863-869 
    Soltani-Arabshahi R, Leboeuf C, Rivet J, Pisonero H,, Bachelez H, Ameisen JC, Janin A  Bcl-xL gene expression correlated with lower apoptotic cell numbers and shorter progression-free survival in PCFCL  J Invest Dermatol.  2009  129(7):1703-9 
    Fu JF, Shi JY,, Li G, Pan Q, Li JM, Hu J, Shen ZX, Jin J, Chen FY, Chen SJ  MassARRAY assay: a more accurate method for JAK2V617F mutation detection in Chinese patients with myeloproliferative disorders  Leukemia  2008  22(3):660-663 
    , Liu YY, Zhang QL, Wang L, Leboeuf C, Zhang YW, Ma J, Garcia JF, Song YP, Li JM, Shen ZX, Chen Z, Janin A, Chen SJ  PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor  Blood  2008  111(7):3867-3871 
    Wang L,, Yan JS, Liu P, Sun HP, Zhou GB, Weng ZY, Wu WL, Weng XQ, Sun XJ, Chen Z, Sun HD, Chen SJ  Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner  Cell Death Differ  2007  14(2): 306-317 
    Liu YY, Leboeuf C, Shi JY, Li JM, Wang L, Shen Y, Garcia JF, Shen ZX, Chen Z, Janin A, Chen SJ,  Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma  Blood  2007  110(1): 339-344 
    , Wang L, Liu YH, Yan JS, Leboeuf C, Liu YY, Wu WL, Janin A, Chen Z, Chen SJ  Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis  Exp Hematol  2007  35(12):1801-11 
    Zhu YM,, Fu JF, Shi JY, Pan Q, Hu J, Gao XD, Chen B, Li JM, Xiong SM, Gu LJ, Tang JY, Liang H, Jiang H, Xue YQ, Shen ZX, Chen Z, Chen SJ  NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis  Clin Cancer Res.  2006  12(10):3043-3049 
    Chen B,, Jin J, Xue YQ, Cheng X, Chen XT, Cui J, Chen ZM, Cao Q, Yang G, Yao Y, Xia HL, Tong JH, Li JM, Chen J, Xiong SM, Shen ZX, Waxman S, Chen Z, Chen SJ  Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries  Leukemia  2005  19(5):767-775 
    , Daneshpouy ME, Mounier N, Brière J, Leboeuf C, Plassa LF, Turpin E, Cayuela JM, Ameisen JC, Gisselbrecht C, Janin A  Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma  Blood  2004  103(2):695-697 
    , Mourah S, Mounier N, Leboeuf C, Daneshpouy ME, Legrès L, Meignin V, Oksenhendler E, Maignin CL, Calvo F, Brière J, Gisselbrecht C, Janin A  Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression  Lab Invest  2004  84(11):1512-1519